fbpx
Canadian Health Coalition
  • Donate
  • Menu Canvas
    • CHC Home
    • News
    • About us
    • Campaigns
    • Take action
    • Contact
  • hello@healthcoalition.ca
  • 343-558-1788
Donate OR Subscribe
    • English
    • Français (French)
Canadian Health Coalition
  • Home
  • About us
    • Our Team
  • News
  • Campaigns
  • Take action
  • Contact
  • Donate

    Support the Canadian Health Coalition

    $
    Select Payment Method
    Personal Info

    Credit Card Info
    This is a secure SSL encrypted payment.

    Donation Total: $55.00 One Time

How Big Pharma uses disinformation to undermine drug price reform: Joel Lexchin

Homepage Analysis How Big Pharma uses disinformation to undermine drug price reform: Joel Lexchin
Analysis

How Big Pharma uses disinformation to undermine drug price reform: Joel Lexchin

January 9, 2023
By Steven Staples
0 Comment
163 Views

In his latest article for The Conversation, Canadian Health Coalition Board Member Dr. Joel Lexchin unpacks the pharmaceutical lobby’s “falsehoods and half truths” about the urgent need for drug control measures in Canada.  


How the pharmaceutical industry uses disinformation to undermine drug price reform

By Joel Lexchin

Canada’s drug prices are the fourth highest in the developed world. Despite this, Innovative Medicines Canada (IMC), the lobby group for Big Pharma, put out a call in November 2022 for the Canadian government to suspend consultations on guidelines aimed at lowering prescription drug prices.

The proposed guidelines were expected to come into effect on Jan. 1, but were postponed in late December.

IMC warned that if the new guidelines went ahead, drug launches would be delayed and “Canadian patients will be deprived of potentially life-saving new medicines.”

Just a few days later, IMC took out a full-page ad in the Globe and Mail claiming that “Canadians wait twice as long for new medicines.”

Falsehoods and half-truths

IMC has been claiming since the end of 2020 that “new drugs are not being launched in Canada” because our drug prices might be lowered. However, between 2011 and 2020, there was no change in the timing between when drugs were approved by the United States Food and Drug Administration (FDA) and then by Health Canada.

Drug companies did not wait longer to introduce new drugs here compared to the U.S. There was a decline in the per cent of drugs first approved by the FDA and then by Health Canada, but the same thing happened in Australia where drug prices were not being lowered.

What about the claim that Canadians are losing out on new potentially life-saving drugs?

Only 10-15 per cent of new drugs are actually major therapeutic breakthroughs. The industry claims the other 85-90 per cent give patients more choice. But companies don’t test their new drugs on patients who can’t tolerate or don’t get better on older ones. So, nobody really knows if those choices mean anything positive for patients.

Wait times

Do Canadians wait longer for new drugs? If the comparison is to patients in the U.S. or the European Union (EU), then the answer is yes.

Why is the wait longer? After companies submit drugs for approval in the U.S. or the EU, they take an extra year before submitting them to Health Canada. Is that wait because of Canadian drug prices? No. Drug prices are higher in Switzerland than in Canada, but the wait to get drugs approved in Switzerland is also longer than in Canada.

If drug prices were the reason for the wait, then companies should be submitting applications sooner in Switzerland compared to Canada.

In Canada, newly approved drugs are available for people with private insurance about a year before they can be prescribed to people covered by provincial/territorial drug formularies. But a substantial proportion of that time difference is in the hands of drug companies.

If pharma companies want to get their drugs publicly covered, they first have to submit them to the Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH then does a value-for-money audit and makes a recommendation to the provinces and territories about funding.

In an effort to speed up decision-making about whether the public should pay for new drugs, ever since April 2018 companies can submit applications to CADTH up to 180 days before Health Canada approves the drugs. But instead of taking full advantage of this provision, companies only submit a median of 13 days before approval, adding 5.5 months to the time it takes to make a final decision.


Stay up-to-date on this and other campaigns



    Protecting profits

    Drug companies have been making threats for over 50 years every time governments do something that threatens their profits.

    In 1972, the NDP government of Manitoba passed a law making it mandatory for pharmacists to substitute cheaper generic drugs for those named on prescriptions, unless prohibited by the physician writing the prescription. Furthermore, the substitute could not be sold at a price higher than that of the lowest priced equivalent drug. After this legislation passed, the president of the industry association made a thinly veiled threat to the Manitoba government:

    “It will remain to be seen how much value would be put on the Manitoba market by research-oriented companies. It is each company’s decision whether the size of their Manitoba market will merit the cost of properly servicing that market. If they can’t meet the prices they could be forced out of business.”

    After the Liberal government in Ontario passed legislation in 2017 requiring companies to report how much money they gave to doctors, hospitals and other health care personnel and institutions, IMC made the same threat about not launching new drugs in Canada because of the regulatory burden of having to make reports.

    Now, they are making a similar threat based on potentially lower drug prices in Canada.

    Drug companies make threats to maintain their ability to make extraordinarily high profits. The rest of us need to stand up for the right of patients to get drugs at affordable prices.

    Joel Lexchin is Professor Emeritus of Health Policy and Management, York University, Canada

    • Read “How the pharmaceutical industry uses disinformation to undermine drug price reform,” by Joel Lexchin, published January 9, 2023 by The Conversation
    Steven Staples is the National Director of Policy and Advocacy for the Canadian Health Coalition
    Tags: Pharmacare

    Previous Story
    Five public health care issues worth watching in 2023
    Next Story
    Put aside politicking and get down to productive discussions: Linda Silas

    Related Articles

    Sign up for the Parliament Hill Lobby for Public Health Care, March 27-29, 2023

    Registration deadline extended to March 8, 2023

    Hundreds rally on Parliament Hill for universal pharmacare and against privatization

    The Canadian Health Coalition wants privatization off the table

    Recent Posts

    • Government leadership can scale-up system improvements: Solutions series, part IV Mar 14, 2023
    • Canada needs a Long-Term Care Insurance Plan: Globe Mar 14, 2023
    • Improve the public system instead of privatization: Solutions series part III Mar 8, 2023
    • “I believe we can rebuild our public health care system”: Jagmeet Singh Mar 7, 2023
    • MPs to vote on health care privatization next Monday, March 6 Mar 1, 2023

    Tags

    Canada Health Transfer Canadian Health Coalition COVID-19 Dental Care Federal Election 44 Health+Hope 2025 Health Care Workers Health Policy Home care Long-term Care Medicare Mental Health Pharmacare Plasma Privatization Racism Reproductive Health Care Solutions series

    Cdn Health Coalition Follow

    HealthCoalition

    Government leadership can scale-up system improvements. Read part 4 of a health care solutions series by @a_longhurst https://www.healthcoalition.ca/government-leadership-can-scale-up-system-improvements-solutions-series-part-iv/

    Reply on Twitter 1636109006505639936 Retweet on Twitter 1636109006505639936 5 Like on Twitter 1636109006505639936 2 Twitter 1636109006505639936
    Canadian Health Coalition
    116 Albert St. Suite 300
    Ottawa, Ontario K1P 5G3
    +343.558.1788
    hello@healthcoalition.ca
    • Home
    • What we do
    • Campaigns
    • News
    • Contact

    Find posts prior to January 1, 2021
    SearchPostsLogin
    Tuesday, 14, Mar
    Government leadership can scale-up system improvements: Solutions series, part IV
    Tuesday, 14, Mar
    Canada needs a Long-Term Care Insurance Plan: Globe
    Wednesday, 8, Mar
    Improve the public system instead of privatization: Solutions series part III
    Tuesday, 7, Mar
    “I believe we can rebuild our public health care system”: Jagmeet Singh
    Wednesday, 1, Mar
    MPs to vote on health care privatization next Monday, March 6
    Tuesday, 28, Feb
    Hospital capacity challenges pre-date the pandemic: Solutions series, part II

    Welcome back,